Skip to main content
Equibles
RXRX logo

RXRX · Recursion Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio

Track RXRX — free

Use RXRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.23 -0.21 (-6.10%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.94B
Shares
535.34M

Recursion Pharmaceuticals, Inc. Earnings Call Transcripts

Quarterly earnings calls for Recursion Pharmaceuticals, Inc. (RXRX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲439.9% $13.68M −$57.49M '22 Q4 23-02-27 ▲127.5% $12.13M −$65.33M '23 Q1 23-05-08 ▼20.4% $10.89M −$93.00M '23 Q4 24-02-27 ▲13.7% $13.79M −$91.37M '24 Q1 24-05-09 ▲30.9% $14.42M −$97.54M '24 Q2 24-08-08 ▼58.3% $4.55M −$178.91M '24 Q4 25-02-28 ▲6.9% $14.74M −$202.49M '25 Q1 25-05-05 ▲33.3% $19.22M −$171.90M '25 Q2 25-08-05 ▼80.2% $5.17M −$162.25M '25 Q3 25-11-05 ▲681.7% $35.54M −$108.12M '25 Q4 26-02-25 ▼56.1% $6.47M −$117.50M '26 Q1 26-05-06 LATEST ▼60.1% $7.67M −$131.00M '26 Q2 26-08-05
Conference
Investor event
2026-09-15
Recursion Pharmaceuticals, Inc. (RXRX) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call
Revenue
$7.67M
▼ 60.1% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Recursion Pharmaceuticals, Inc. (RXRX) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript
Confident tone AI-native product engine and platform Wholly owned clinical pipeline Clinical proof points and catalysts
Revenue
$6.47M
▼ 56.1% YoY
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript
Confident tone Upcoming catalysts and FDA engagement Sanofi partnership and milestones Clinical pipeline and FAP proof of concept
Revenue
$35.54M*
▲ 681.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript
Confident tone Roche/Genentech partnership & milestones CEO leadership transition Partnership strategy (incl. Sanofi, new deals)
Revenue
$5.17M
▼ 80.2% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript
Confident tone Internal pipeline programs Recursion OS platform Boltz-2 partnership and open source
Revenue
$19.22M
▲ 33.3% YoY
Diluted EPS
$-0.41
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript
Positive tone Discontinued Programs Pharma Partnerships Rare Disease / FAP Program
Revenue
$14.74M
▲ 6.9% YoY
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-28
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript
Confident tone TechBio platform and AI/ML capabilities Pharma partnerships and milestones NIH funding concerns and ecosystem risk
Revenue
$4.55M*
▼ 58.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-08-08
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
Confident tone Pharma partnerships Pipeline and clinical readouts Exscientia combination
Revenue
$14.42M
▲ 30.9% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript
Confident tone Industry outlook and competition Strategic partnerships and collaborations Platform and data layers
Revenue
$13.79M
▲ 13.7% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2023 Earnings Call Transcript
Confident tone Partnerships TechBio platform and Recursion OS Pipeline and clinical milestones
Revenue
$10.89M*
▼ 20.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q1
2023-05-08
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2023 Earnings Call
Revenue
$12.13M
▲ 127.5% YoY
Diluted EPS
$-0.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2022 Earnings Call
Revenue
$13.68M*
▲ 439.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–14 of 14 earnings calls
Key facts CIK 1601830 CUSIP 75629V104 13F (30d) 194 filings 194 filers Visit website Investor relations